Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Expert Rev Hematol ; 15(1): 33-43, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-34904506

RESUMEN

INTRODUCTION: The modern treatment of patients with primary central nervous system lymphoma (PCNSL) consists of two phases: induction, currently represented by a high-dose-methotrexate-based polychemotherapy, and consolidation. The optimal consolidation therapy has not been defined yet, but several strategies, such as whole-brain radiotherapy (WBRT), high-dose chemotherapy supported by autologous stem cell transplantation (HDC/ASCT) or nonmyeloablative chemotherapy, have been addressed in important randomized trials. AREAS COVERED: This review provides an overview of the current role of consolidation strategies in young and fit patients with newly diagnosed PCNSL. Publications in English language, peer-reviewed, from high-quality international journals, edited from 2003 to 2021 were identified on PubMed. EXPERT OPINION: Consolidation treatment significantly improved outcomes of PCNSL. Radiotherapy had represented for years the only choice in the consolidation therapy, but large randomized trials have demonstrated that HDC/ASCT is equally effective and associated with lower neurotoxicity risk in patients younger than 65-70 years. Encouraging results have been obtained using reduced-dose WBRT, while a recent randomized trial failed to demonstrate that consolidation with nonmyeloablative chemotherapy is more effective than HDC/ASCT in PCNSL patients. A personalized consolidation treatment, driven also by a response prediction model based on radiological and molecular details, may improve the management of PCNSL patients.


Asunto(s)
Neoplasias del Sistema Nervioso Central , Trasplante de Células Madre Hematopoyéticas , Linfoma , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Sistema Nervioso Central/patología , Neoplasias del Sistema Nervioso Central/diagnóstico , Neoplasias del Sistema Nervioso Central/terapia , Terapia Combinada , Trasplante de Células Madre Hematopoyéticas/métodos , Humanos , Linfoma/tratamiento farmacológico , Linfoma/terapia , Metotrexato/uso terapéutico , Trasplante Autólogo
2.
Leuk Res Rep ; 16: 100263, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34401320

RESUMEN

Primary adrenal lymphoma (PAL) and primary renal lymphoma (PRL) are rare extranodal lymphomas, predominantly of diffuse large B-cell lymphoma subtype. Primary adrenal and renal lymphomas (PARL) exhibit a high predilection for the central nervous system (CNS). Therefore, current guidelines support the use of CNS prophylaxis in PARL, particularly in cases of high-risk Central Nervous System International Prognostic Index (CNS-IPI). However, the route of administration (i.e. systemic vs. intrathecal chemotherapy) has not been clearly elucidated. With this in mind, we initiated an international collaboration and literature review to analyze 50 patient cases, 20 of which received CNS prophylaxis. Based on our analysis, we conclude that PARL may indicate a need for CNS chemo-prophylaxis in the form of systemic high-dose methotrexate (HD-MTX) over intrathecal methotrexate (IT-MTX), although IT-MTX may still have utility in certain cases.

3.
Recenti Prog Med ; 104(5): 203-8, 2013 May.
Artículo en Italiano | MEDLINE | ID: mdl-23748685

RESUMEN

Within diffuse large B-cell lymphomas, the Primary Mediastinal Large B-Cell Lymphoma has to be considered as a separate and well-defined clinico-pathological entity. Its tendency to target young adults makes its social impact particularly significant; hence, the General Practitioner carries the responsibility for an early diagnosis. On the contrary, the extreme complexity of the available therapies makes a quick referral to specialized Clinical Centres of outmost importance, since this remains the best way to enrol as many patients as possible in therapeutic protocols. Nowadays, good clinical results and a favourable outcome are achievable, but some questions remain open. The role of radiotherapy still has to be clarified, both as a complete remission consolidation, as well as a treatment of the residual disease. Conversely, a golden standard for the second line treatment has not been clearly established.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Linfoma de Células B Grandes Difuso/terapia , Neoplasias del Mediastino/terapia , Anticuerpos Monoclonales de Origen Murino/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Bleomicina/administración & dosificación , Quimioradioterapia , Dolor en el Pecho/etiología , Ciclofosfamida/administración & dosificación , Diagnóstico por Imagen , Doxorrubicina/administración & dosificación , Disnea/etiología , Diagnóstico Precoz , Humanos , Inmunofenotipificación , Leucovorina/administración & dosificación , Linfoma de Células B Grandes Difuso/diagnóstico , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Linfoma de Células B Grandes Difuso/epidemiología , Linfoma de Células B Grandes Difuso/radioterapia , Neoplasias del Mediastino/diagnóstico , Neoplasias del Mediastino/tratamiento farmacológico , Neoplasias del Mediastino/epidemiología , Neoplasias del Mediastino/radioterapia , Metotrexato/administración & dosificación , Estudios Multicéntricos como Asunto , Estadificación de Neoplasias , Prednisona/administración & dosificación , Pronóstico , Ensayos Clínicos Controlados Aleatorios como Asunto , Rituximab , Terapia Recuperativa , Evaluación de Síntomas , Vincristina/administración & dosificación
4.
Nat Clin Pract Oncol ; 5(10): 619-22, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18725922

RESUMEN

BACKGROUND: A 45-year-old man underwent a right orchiectomy for a rapidly growing testicular mass. After histologic and imaging examinations the patient was diagnosed with stage I (T1N0M0) seminoma. Approximately 2 months after surgery the patient began to complain of abdominal pain and a CT scan revealed a bulky retroperitoneal mass. The patient did not receive the planned prophylactic radiotherapy and was treated with combined cisplatin, etoposide and bleomycin chemotherapy; after the completion of this treatment he achieved complete remission. Three years later, and while still undergoing follow-up, the patient developed multiple neurological motor deficits. INVESTIGATIONS: Brain MRI and CT-guided biopsy. DIAGNOSIS: Diffuse large B-cell lymphoma of the testis, relapsing in the central nervous system. MANAGEMENT: High-dose methotrexate alone or in combination with high-dose cytarabine.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Linfoma de Células B Grandes Difuso/diagnóstico , Seminoma/tratamiento farmacológico , Neoplasias Testiculares/diagnóstico , Neoplasias Testiculares/tratamiento farmacológico , Antígenos CD20/metabolismo , Bleomicina/administración & dosificación , Encéfalo/diagnóstico por imagen , Cisplatino/administración & dosificación , Citarabina/administración & dosificación , Diagnóstico Diferencial , Etopósido/administración & dosificación , Resultado Fatal , Humanos , Inmunohistoquímica , Factores Reguladores del Interferón/metabolismo , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Linfoma de Células B Grandes Difuso/patología , Masculino , Metotrexato/administración & dosificación , Persona de Mediana Edad , Orquiectomía , Radiografía , Recurrencia , Inducción de Remisión , Seminoma/diagnóstico , Seminoma/patología , Seminoma/cirugía , Neoplasias Testiculares/patología , Neoplasias Testiculares/cirugía
5.
Hematol Oncol ; 24(1): 33-7, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16385613

RESUMEN

BACKGROUND: The prevalence and the clinical impact of gastric Helicobacter pylori (Hp) infection, as well as its possible correlation with Chlamydia psittaci (Cps) infection and the lymphoma regression rate produced by Hp eradicating antibiotic therapy were investigated in patients with MALT-type lymphoma of the ocular adnexa (OAL). METHODS: During staging, the presence of gastric Hp infection was assessed by gastroscopy and multiple biopsies in 31 OAL patients. Immediately after, Hp-positive patients were treated with eradicating antibiotic therapy, alone or associated with other therapies. RESULTS: Gastric Hp infection was detected in 10 (32%) patients; this feature did not correlate with patients' characteristics and disease. Four Hp-positive patients were treated with Hp-eradicating antibiotics therapy as exclusive strategy (assessable for response), none of them showed lymphoma regression. Conversely, 6 Hp-positive patients were treated with antibiotic therapy concurrently with other therapies, achieving lymphoma regression in all cases. Three Hp-positive patients with Cps-positive lymphoma were treated with doxycycline at relapse, resulting in two CR and one PR, which lasted 24+, 20+, and 18+ months, respectively. One of these patients achieved a CR after doxycycline despite the chronic persistence of Hp infection, whereas Cps-eradication was confirmed in the analysis of PBMC samples. CONCLUSIONS: Gastric Hp infection, even if common among OAL patients, does not influence clinical presentation. Hp-eradicating antibiotic therapy is not active against OAL. Cps-eradicating antibiotic therapy with doxycycline induces lymphoma remission irrespectively of the persistence of Hp infection.


Asunto(s)
Enfermedades de la Conjuntiva/microbiología , Infecciones por Helicobacter/complicaciones , Helicobacter pylori/aislamiento & purificación , Linfoma de Células B de la Zona Marginal/microbiología , Enfermedades Orbitales/microbiología , Neoplasias Gástricas/microbiología , Adulto , Anciano , Antibacterianos/uso terapéutico , Supervivencia sin Enfermedad , Doxiciclina/farmacología , Femenino , Gastroscopía , Infecciones por Helicobacter/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Terapia Recuperativa , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...